AML Biomarkers: How Testing Shapes Your Treatment Options
Webinar on Wednesday, June 18th | 3pm PDT / 6pm EDT
Hear a Patient-Physician Perspective – Follow Joseph’s journey and learn how a doctor makes decisions when he’s the patient.
Join AML expert Dr. Stephen Strickland from Sarah Cannon Research Institute, AML patient and doctor Joseph, and advocate Steve Buechler to learn how biomarker testing can unlock better options. Learn how understanding what mutation you have, like NPM1, IDH, KMT2A, and RUNX1 can shape treatment choices—and how patients can work with their doctors to explore every option, including clinical trials.
Key Topics:
- Understand AML Biomarkers – Learn how FLT3, NPM1, IDH1/2, and KMT2A mutations impact risk and treatment choices
- Test Early, Treat Smarter – See how early biomarker testing shapes decisions from day one
- Explore Targeted Treatment Options – Understand how biomarker-driven therapies are changing care
- Navigate Clinical Trials with Confidence – Learn how to evaluate opportunities and what trial participation really looks like
- Partner with Your Care Team – Get tips to advocate for testing and align on a personalized treatment path
We would like to thank The Leukemia & Lymphoma Society for their partnership.
The LLS offers free resources like its Information Specialists, who are one free call away for support in different areas of blood cancer.
